Literature DB >> 23875742

Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives.

Amir Sharafkhaneh1, Ray A Wolf, Sheila Goodnight, Nicola A Hanania, Barry J Make, Donald P Tashkin.   

Abstract

Although delivery of medications through nebulization is effective for patients with COPD, nebulization is often perceived negatively. This survey evaluated patient and caregiver attitudes and perceptions related to the use of nebulization for the management of COPD. A total of 400 patients and a separate population of 400 caregivers were randomly selected and interviewed via telephone. Responses were assessed on the basis of 4 domains: health of patients with COPD, satisfaction with nebulization therapy, benefits and challenges, and the caregiver role. Most patients (58%) self-classified their COPD as "mild to moderate," with shortness of breath upon minimal to moderate exertion; caregivers reported similar findings. The majority of patients and caregivers (89% and 92%, respectively) were "generally satisfied with their (or their friend's or family member's) current nebulized treatment." Based on their personal experiences, 80% of patients and caregivers reported that using a nebulizer was better than using only an inhaler. Patients and caregivers agreed (79% and 85%, respectively) that the benefits of nebulization therapy outweighed the difficulties or inconveniences. Patients believed that their overall quality of life had improved since beginning nebulization (75%) and that nebulization better enabled their caregiver to provide care (77%); caregivers echoed this sentiment. Overall, this survey demonstrated that an overwhelming majority of patients and caregivers were satisfied with nebulization therapy, reporting benefits in symptom relief, ease of use, and improved quality of life.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23875742     DOI: 10.3109/15412555.2013.773302

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  15 in total

1.  Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Authors:  Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin
Journal:  Chronic Obstr Pulm Dis       Date:  2016-11-15

Review 2.  Update on management of stable chronic obstructive pulmonary disease.

Authors:  Ritwick Agrawal; Shahram Moghtader; Uma Ayyala; Venkata Bandi; Amir Sharafkhaneh
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Initial medication non-adherence: prevalence and predictive factors in a cohort of 1.6 million primary care patients.

Authors:  Ignacio Aznar-Lou; Ana Fernández; Montserrat Gil-Girbau; Marta Fajó-Pascual; Patricia Moreno-Peral; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Albert Sánchez-Niubó; María Antonia March-Pujol; Anna Maria Jové; Maria Rubio-Valera
Journal:  Br J Clin Pharmacol       Date:  2017-02-24       Impact factor: 4.335

4.  Assistance of family carers for patients with COPD using nebulisers at home: a qualitative study.

Authors:  Bothaina Alhaddad; Kevin Mg Taylor; Tricia Robertson; Geoffrey Watman; Felicity J Smith
Journal:  Eur J Hosp Pharm       Date:  2015-11-02

5.  Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event.

Authors:  Maryam Navaie; Bartolome R Celli; Zhun Xu; Soojin Cho-Reyes; Carole Dembek; Todd P Gilmer
Journal:  Chronic Obstr Pulm Dis       Date:  2019-10-23

Review 6.  A review of nebulized drug delivery in COPD.

Authors:  Donald P Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-18

Review 7.  Recent advances in the management of chronic obstructive pulmonary disease.

Authors:  Sharon R Rosenberg; Ravi Kalhan
Journal:  F1000Res       Date:  2017-06-09

Review 8.  Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease.

Authors:  Pierachille Santus; Dejan Radovanovic; Andrea Cristiano; Vincenzo Valenti; Maurizio Rizzi
Journal:  Drug Des Devel Ther       Date:  2017-11-15       Impact factor: 4.162

9.  Exploring medicines management by COPD patients and their social networks after hospital discharge.

Authors:  Ellen Ingrid Schafheutle; Tom Fegan; Darren M Ashcroft
Journal:  Int J Clin Pharm       Date:  2018-07-28

10.  Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment.

Authors:  Bartolome R Celli; Maryam Navaie; Zhun Xu; Soojin Cho-Reyes; Carole Dembek; Todd P Gilmer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.